Incannex Healthcare Inc. (Nasdaq: IXHL) reported positive results from its Phase 2 Psi-GAD1 clinical trial assessing psilocybin’s efficacy in treating generalized anxiety disorder. The psilocybin group experienced a significant decrease in anxiety, with 44% seeing at least a 50% reduction, compared to the placebo group. The company plans a subsequent Phase 2B trial, PsiGAD2, in collaboration with Clerkenwell Health.
Read the full story here
Written by: Adam Jackson
Published on February 29, 2024 at 04:11AM
Source: Green Market Report (opens in new tab)